Ena nucleic acid pharmaceuticals capable of modifying...

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/11 (2006.01) A61K 31/7088 (2006.01) A61K 31/712 (2006.01) A61K 31/7125 (2006.01) A61K 48/00 (2006.01) A61P 21/04 (2006.01) C07H 21/04 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2507125

Oligonucleotides having base sequences complementary to dinucleotide Nos. 2571- 2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601, 2575-2592, etc. of dystrophin cDNA (Gene Bank accession No. NM_004006.1) and remedies for muscular dystrophy containing the same.

L'invention concerne des oligonucléotides ayant des séquences de base complémentaires des dinucléotides No 2571-2607, 2578-2592, 2571-2592, 2578-2596, 2578-2601, 2575-2592, etc. de dystrophine ADNc (accession à Banque de gènes No NM 004006.1). L'invention concerne également des remèdes pour la dystrophie musculaire contenant les composés précités.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Ena nucleic acid pharmaceuticals capable of modifying... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ena nucleic acid pharmaceuticals capable of modifying..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ena nucleic acid pharmaceuticals capable of modifying... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1996417

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.